[HTML][HTML] Approaches, progress, and challenges to hepatitis C vaccine development
Risk factors for hepatitis C virus (HCV) infection vary, and there were an estimated 1.75
million new cases worldwide in 2015. The World Health Organization aims for a 90 …
million new cases worldwide in 2015. The World Health Organization aims for a 90 …
Identification and characteristics of fusion peptides derived from enveloped viruses
C Lozada, TMA Barlow, S Gonzalez… - Frontiers in …, 2021 - frontiersin.org
Membrane fusion events allow enveloped viruses to enter and infect cells. The study of
these processes has led to the identification of a number of proteins that mediate this …
these processes has led to the identification of a number of proteins that mediate this …
Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate
Hepatitis C virus (HCV) infection affects approximately 58 million people and causes~
300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly …
300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly …
Structure of the hepatitis C virus E1E2 glycoprotein complex
Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease, cirrhosis, and
hepatocellular carcinoma in humans and afflicts more than 58 million people worldwide. The …
hepatocellular carcinoma in humans and afflicts more than 58 million people worldwide. The …
Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies
MC Metcalf, BM Janus, R Yin, R Wang… - Nature …, 2023 - nature.com
Hepatitis C virus (HCV) is a major global health burden as the leading causative agent of
chronic liver disease and hepatocellular carcinoma. While the main antigenic target for HCV …
chronic liver disease and hepatocellular carcinoma. While the main antigenic target for HCV …
[HTML][HTML] HCV broadly neutralizing antibodies use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design
Hepatitis C virus (HCV) vaccine efforts are hampered by the extensive genetic diversity of
HCV envelope glycoproteins E1 and E2. Structures of broadly neutralizing antibodies …
HCV envelope glycoproteins E1 and E2. Structures of broadly neutralizing antibodies …
Broadly neutralizing antibody mediated clearance of human hepatitis C virus infection
The role that broadly neutralizing antibodies (bNAbs) play in natural clearance of human
hepatitis C virus (HCV) infection and the underlying mechanisms remain unknown. Here, we …
hepatitis C virus (HCV) infection and the underlying mechanisms remain unknown. Here, we …
Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies
An effective vaccine to the antigenically diverse hepatitis C virus (HCV) must target
conserved immune epitopes. Here, we investigate cross-neutralization of HCV genotypes by …
conserved immune epitopes. Here, we investigate cross-neutralization of HCV genotypes by …
Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and …
Cumulative evidence supports a role for neutralizing antibodies contributing to spontaneous
viral clearance during acute hepatitis C virus (HCV) infection. Information on the timing and …
viral clearance during acute hepatitis C virus (HCV) infection. Information on the timing and …
Antigenicity and immunogenicity of differentially glycosylated hepatitis C virus E2 envelope proteins expressed in mammalian and insect cells
RA Urbanowicz, R Wang, JE Schiel, Z Keck… - Journal of …, 2019 - Am Soc Microbiol
The development of a prophylactic vaccine for hepatitis C virus (HCV) remains a global
health challenge. Cumulative evidence supports the importance of antibodies targeting the …
health challenge. Cumulative evidence supports the importance of antibodies targeting the …